Evolution of docetaxel-based therapy for metastatic castrate-resistant prostate cancer

British Journal of Medical and Surgical Urology

Volumn 3, Issue 6, 2010, Pages 225-230

  Cornford, Philip ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Castrate resistant prostate cancer; Chemotherapy; Docetaxel

Indexed keywords

AMINOGLUTETHIMIDE; BEVACIZUMAB; CETUXIMAB; CYTARABINE; DIETHYLSTILBESTROL; DOCETAXEL; EPOTHILONE B; ESTRAMUSTINE; HYDROCORTISONE; KETOCONAZOLE; MITOXANTRONE; MONOCLONAL ANTIBODY J591; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; NAVELBINE; OGX 011; PREDNISONE; SATRAPLATIN; SUNITINIB;

ADJUVANT THERAPY; ADVANCED CANCER; BONE PAIN; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CASTRATE RESISTANT PROSTATE CANCER; CASTRATION; CLINICAL TRIAL; HORMONAL THERAPY; HUMAN; MAINTENANCE THERAPY; MEDICAL RESEARCH; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT RESPONSE;

EID: 77957750183     PISSN: 18759742     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bjmsu.2010.08.007     Document Type: Review

References (32)

1. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
2. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
3. Persad R., Bahl A. Modern chemotherapy strategies for management of 'hormone resistant prostate cancer' (HRPC)-when should the urologist refer?. Br J Med Surg Urol 2009, 2:92-99.
4. Yagoda A., Petrylak D.P. Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer 1993, 71:1098-1109.
5. Kantoff P.W., Halabi S., Conaway M., Picus J., Kirshner J., Hars V., et al. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results of Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999, 17:2506-2513.
6. Abratt R.P., Brune D., Dimopoulos M.A., Kliment J., Breza J., Selvaggi F.P., et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone refractory prostate cancer. Ann Oncol 2004, 15:1613-1621.
7. Picus J., Schultz M. Docetaxel (Taxotere) as a monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999, 26:14-18.
8. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008, 26:242-245.
9. National Institute for Health and Clinical Excellence Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (Technology Appraisal 101) 2006, [June].
10. Bahl A., Bertelli G., Lewis P., Jenkins P., Hudson E., Davies P.J., et al. Presence or absence of symptoms is a major determinant of survival in metastatic castration resistant prostate cancer (CRPC) treated with docetaxel chemotherapy. Interim results of a pooled study from 4 UK centres. Poster presented at the American Society of Clinical Oncology 2009.
11. Heidenreich A., Aus G., Bolla M., Joniau S., Matveev V.B., Schmid H.P., et al. EAU guidelines on prostate cancer. Eur Urol 2008, 53:68-80.
12. Calabro F., Sternberg C.N. Current indications for chemotherapy in prostate cancer patients. Eur Urol 2007, 51:17-26.
13. de Wit R. Chemotherapy in hormone-refractory prostate cancer. BJU Int 2009, 101:11-15.
14. National Institute for Health and Clinical Excellence Prostate cancer: diagnosis and treatment (Clinical Guidance 58) 2008, [February].
15. Oudard S., Banu E., Medioni J., Scotte F., Banu A., Levy E., et al. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?. BJU Int 2009, 103:1641-1646.
16. de Wit R. New hope for patients with metastatic hormone-refractory prostate cancer. Eur Urol Suppl 2006, 5:817-823.
17. Extermann M., Albrand G., Chen H., Zanetta S., Schonwetter R., Zulian G.B., et al. Are older French patients as willing as older American patients to undertake chemotherapy?. J Clin Oncol 2003, 21:3214-3219.
18. Shepard D.R., Weil A., Garcia J., Drecier R., Raghavan D. Docetaxel efficacy/toxicity in patients aged 70-85 years with metastatic prostate cancer. Am Soc Clin Oncol-Genitourin 2009, [Abstract 213].
19. Lau Y.K., Chadha M.K., Litwin A., Trump D.L. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature. J Hematol Oncol 2008, 1:21.
20. Serrate C., Loriot Y., De La Motte Rouge T., Gross-Goupil M., Massard C., Escudier B., et al. Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer. Ann Oncol 2009, 20:965.
21. Galsky M.D., Simon K., Sonpavde G., Hutson T.E., Fleming M., Kondagunta G.V., et al. Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer. Ann Oncol 2009, 20:965-966.
22. Beekman K.W., Fleming M.T., Scher H.I., Slovin S.F., Ishill N.M., Heller G., et al. Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer 2005, 4:86-90.
23. Ansari J., Choo B., Hussain A., Zarkar A., Ansari A., Tanquay J.S., et al. Docetaxel retreatment as second- and third-line chemotherapy in metastatic hormone refractory prostate cancer patients pretreated with docetaxel: an updated analysis. Am Soc Clin Oncol-Genitourin 2009, [Abstract 185].
24. De Bono J.S., Oudard S., Ozguroglu M., et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC). Am Soc Clin Oncol 2010, [Abstract and presentation 4508].
25. Clinicaltrials.gov. Study to evaluate safety and feasibility of using OGX-011 in combination with second line chemotherapy in patients with HRPC. [accessed 18.02.10]. http://clinicaltrials.gov/ct2/show/NCT00327340%3Fterm=With+Second+Line+Chemotherapy+in+Patients+With+HRPC%26rank=1.
26. Clinicaltrials.gov. Docetaxel/prednisone plus fractionated 177Lu- J591 antibody for metastatic, castrate-resistant prostate cancer. [accessed 18.02.10]. http://clinicaltrials.gov/ct2/show/NCT00916123.
27. Clinicaltrials.gov. Satraplatin and bevacizumab in treating patients with metastatic prostate cancer previously treated with docetaxel. [accessed 18.02.10]. http://clinicaltrials.gov/ct2/show/NCT00499694%3Fterm=antibody+%252B+chemotherapy%26cond=prostate+cancer%26rank=6.
28. Clinicaltrials.gov. Study of patupilone in prostate cancer patients who progress after hormone therapy and docetaxel chemotherapy. [accessed 18.02.10]. http://clinicaltrials.gov/ct2/show/NCT00407251%3Fterm=Study+of+Patupilone+in+Prostate+Cancer+Patients+Who+Progress+After%26rank=1.
29. Clinicaltrials.gov. Sunitinib plus prednisone in patients with metastatic hormone-refractory prostate cancer after failure of docetaxel chemotherapy (SUN 1120). [accessed 18.02.10]. http://clinicaltrials.gov/ct2/show/NCT00676650%3Fterm=Sunitinib+Plus+Prednisone+In+Patients+With+Metastatic+Hormone%26rank=1.
30. Clinicaltrials.gov. A phase II study of ara-c (Cytarabine) in men with androgen independent prostate cancer (SLAP). [accessed 18.02.10]. http://clinicaltrials.gov/ct2/show/NCT00480090%3Fterm=A+Phase+II+Study+of+Ara-C+%2528Cytarabine%2529+in+Men+With+Androgen%26rank=1.
31. Clinicaltrials.gov. Mitoxantrone ± cetuximab 2nd line androgen independent prostate cancer (AIPC). [accessed 18.02.10]. http://clinicaltrials.gov/ct2/show/NCT00661492%3Fterm=Mitoxantrone+%25C2%25B1+Cetuximab+2nd+Line+Androgen+Independent+Prostate+cancer%26rank=1.
32. Clinicaltrials.gov. A phase III trial of ZD4054 (endothelin a antagonist) and docetaxel in metastatic hormone resistant prostate cancer (ENTHUSEM1C). [accessed 10.02.10]. http://clinicaltrials.gov/ct2/show/NCT00617669%3Fterm=docetaxel+%252B+ZD4054%26rank=2.